Safety and efficacy of bevacizumab combined with R-CHOP regimen in seven Chinese patients with untreated diffuse large B-cell lymphoma

BACKGROUND: Rituximab plus CHOP (R-CHOP) significantly improved the outcome of diffuse large B cell lymphoma (DLBCL), a common sub-type of non-Hodgkin lymphoma. But 40% – 50% of DLBCL patients cannot be cured by this regimen. Some clinical trials showed that bevacizumab might be useful in the treatm...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Fu, Zhiying, Zhu, Jun, Zheng, Wen, Liu, Weiping, Ying, Zhitao, Xie, Yan, Wang, Xiaopei, Lin, Ningjing, Tu, Meifeng, Ping, Lingyan, Deng, Lijuan, Zhang, Chen, Ding, Ning, Song, Yuqin
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2014
Teme:
Primary Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3897913/
https://ncbi.nlm.nih.gov/pubmed/24438119
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1475-2867-14-5
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items